TO

Targeted Oncology

Targeted Oncology publishes oncology and cancer research focused on molecularly targeted agents and related pathways, including pre-clinical and clinical Original Research Articles, narrative Review Articles, Systematic Reviews using PRISMA methods, Adis Drug Reviews, and Letters to the Editor. The journal serves physicians and scientists working on targeted therapies, oncogenic pathways, immune checkpoints, and biomarkers of treatment success.

Looking to publish in Targeted Oncology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 4
Quartile Q2
Open Access Type Hybrid
ISSN 1776-2596
eISSN 1776-260X
Invitation Only No
Cost Range Open access APC: £3190.00 GBP / $5190.00 USD / €3990.00 EUR; subscription publishing: no APC.

Submission Instructions

Targeted Oncology accepts the following article types. Click on an article type to view submission instructions.

Review Article

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required and must be 150 to 250 words. Abstract must be 150 to 250 words. Abstract must be unstructured and contain no headings.
Manuscript Review Article manuscripts should be up to 8000 words. Manuscript must include Key Points, a Declarations section, a disclosure statement, a statement of responsibility specifying every author's contribution, a statement identifying who conceived the article, performed the literature search and data analysis, and drafted and/or critically revised the work, and documentation of any large language model use in the Methods section or another suitable section.
References There is no limit on the number of references. Citations must be numbered in square brackets. Reference list entries must be numbered consecutively and include only cited works that have been published or accepted for publication, with full DOI links when available.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Tables and figures must be numbered with Arabic numerals, cited in consecutive numerical order, and each must have a caption, with figure captions included in the manuscript text file rather than in the figure file.
Reformat to Targeted Oncology using Livewrite Premium

Systematic Review

Cover Letter Cover Letter requirements are not specified.
Abstract An abstract is required for Systematic Reviews. Abstract may be up to 450 words if needed for full compliance with reporting guidelines.
Manuscript Systematic Review manuscripts should be up to 10,000 words. The manuscript must include a statement of responsibility specifying the contribution of every author, a disclosure statement, documentation of any large language model use in the Methods section or another suitable section if no Methods section is available, key points under the heading "Key Points," and a Declarations section.
References There is no limit on the number of references. References must be cited in the text using numbered square brackets. Reference list entries must be numbered consecutively and include only works cited in the text that have been published or accepted for publication.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Tables and figures must be numbered with Arabic numerals, cited in consecutive numerical order in the text, and accompanied by captions.
Reformat to Targeted Oncology using Livewrite Premium

Original Research

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must be 150 to 250 words, but for Original Research it may be increased to up to 450 words if needed for full compliance with reporting guidelines. Abstract must be structured.
Manuscript Original Research manuscripts should be up to 6000 words. Manuscript must include a disclosure statement, a Data Availability Statement explaining how to access supporting data with links or citations to archived datasets where applicable, a Declarations section, Key Points, and documentation of any large language model use in the Methods section or another suitable section.
References There is no limit on the number of references. References must be cited in the text using numbers in square brackets and listed consecutively in a numbered reference list containing only cited works that have been published or accepted for publication, with full DOI links included when available.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Figures and tables must be numbered with Arabic numerals and cited in the text in consecutive numerical order, and each must have a caption or legend with figure captions included in the manuscript text file.
Reformat to Targeted Oncology using Livewrite Premium

Adis Drug Reviews

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must be 150 to 250 words.
Manuscript Manuscript must include a statement of responsibility specifying the contribution of every author, a disclosure statement, a 'Declarations' section, and two to three non-technical bullet points under the heading 'Key Points'.
References There is no limit on the number of references. References must be cited in the text using numbers in square brackets and listed consecutively in a numbered reference list.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Tables and figures must be numbered with Arabic numerals in consecutive order and each must include a caption, with figure captions provided in the manuscript text file.
Reformat to Targeted Oncology using Livewrite Premium

Therapy In Practice Articles

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must be 150 to 250 words.
Manuscript Manuscript should be up to 5000 words. Manuscript must include a statement of responsibility specifying the contribution of every author, a disclosure statement, key points under the heading "Key Points," and declarations under a "Declarations" or "Statements and Declarations" heading, including documentation of any large language model use in the Methods section or another suitable section if no Methods section is available.
References There is no limit on the number of references. Citations must be numbered in square brackets in the text, and the reference list must be numbered consecutively and include only cited works that have been published or accepted for publication.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Tables and figures must be numbered with Arabic numerals in the order cited in the text, each table must have a caption, and each figure must have a concise descriptive caption provided in the manuscript text file rather than in the figure file.
Reformat to Targeted Oncology using Livewrite Premium

Letter To The Editor

Cover Letter Cover letter must mention any unpublished material included in the manuscript.
Abstract Abstract must be 150 to 250 words.
Manuscript Letter To The Editor submissions should be up to 1000 words. Manuscript must include a 'Declarations' section and two to three short bullet points under the heading 'Key Points'.
References There is no limit on the number of references. Citations must be numbered in square brackets in the text and the reference list must be numbered consecutively.
Figures & Tables There is no limit on the number of tables or figures. Figures should be submitted within the body of the text unless file size causes upload problems, in which case large figures should be submitted separately. Tables and figures must be numbered with Arabic numerals and accompanied by captions.
Reformat to Targeted Oncology using Livewrite Premium

Recent Publications

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis

Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Po-Hsin Lee, I-Hung Lin, Mu-Han Peng, Tsung-Ying Yang

10.1007/s11523-026-01224-1
View Publication

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker

Hiroki Ishihara, Takayuki Nakayama, Hironori Fukuda, Nanaka Katsurayama, Yuki Nemoto, Shinsuke Mizoguchi, Hiroaki Shimmura, Yasunobu Hashimoto, Atsuko Seki, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Yoji Nagashima, Toshio Takagi

10.1007/s11523-026-01226-z
View Publication

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Michael A. Liu, Kyle Miyazaki, Karie Runcie, Hanna Cash, Lingbin Meng

10.1007/s11523-026-01228-x
View Publication

Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review

Chin Hang Yiu, Gwyneth Yuet Yin Leung, Isabelle C. Lee, Christine Y. Lu

10.1007/s11523-026-01227-y
View Publication

Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial

Yu Sunakawa, Hisateru Yasui, Manabu Shiozawa, Hiroyuki Takeda, Naoya Akazawa, Tamotsu Sagawa, Kazuhiro Shiraishi, Takahisa Kyogoku, Takashi Mine, Yasuhiro Yuasa, Takanori Watanabe, Tatsuya Kinjo, Yoshihiro Okita, Hiroyuki Okuyama, Satoshi Yuki, Koki Miyakawa, Ayana Kobara, Shoko Yanaka, Yukiko Abe, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji

10.1007/s11523-026-01223-2
View Publication

Frequently asked questions

How long does it take to publish?

Articles are published online after receipt of the corrected proofs.

Reformat to Targeted Oncology using Livewrite Premium

Is a cover letter required?

A cover letter is mentioned for including unpublished material and reviewer suggestions in the submission letter.

Reformat to Targeted Oncology using Livewrite Premium

What are the publication costs?

Open access APC: £3190.00 GBP / $5190.00 USD / €3990.00 EUR. Subscription publishing has no APC.

Reformat to Targeted Oncology using Livewrite Premium

Research Topics

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies HER2/EGFR in Cancer Research Renal cell carcinoma treatment Cancer Genomics and Diagnostics Lung Cancer Diagnosis and Treatment Gastric Cancer Management and Outcomes Advanced Breast Cancer Therapies Hepatocellular Carcinoma Treatment and Prognosis Prostate Cancer Treatment and Research PI3K/AKT/mTOR signaling in cancer Pancreatic and Hepatic Oncology Research Chronic Lymphocytic Leukemia Research Melanoma and MAPK Pathways PARP inhibition in cancer therapy Monoclonal and Polyclonal Antibodies Research Cancer Treatment and Pharmacology Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis Lymphoma Diagnosis and Treatment Neuroendocrine Tumor Research Advances Bladder and Urothelial Cancer Treatments CAR-T cell therapy research

Related Journals

CD
Cancer Discovery American Association for Cancer Research
Ne
Neuro-Oncology Oxford University Press
ER
Endocrine Related Cancer Bioscientifica
JO
Journal of Hepatocellular Carcinoma Dove Medical Press
PT
Pulmonary Therapy Adis, Springer Healthcare
JO
Journal of Thoracic Oncology Elsevier BV